Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, No. 1 Dong Jiao Min Xiang Street, Dongcheng District, Beijing, 100730, People's Republic of China.
Ophthalmology Department, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian, Haidian District, Beijing, 100038, People's Republic of China.
BMC Ophthalmol. 2023 Apr 21;23(1):172. doi: 10.1186/s12886-023-02890-9.
To compare the clinical outcomes of posterior chamber phakic intraocular lens (pIOL) implantation for non-pathological myopia and pathological myopia.
This retrospective case series study which were conducted in Beijing Tongren Eye Center between July 2017 and Oct 2021 comprised 192 eyes of 100 consecutive patients undergoing pIOL implantation. Eyes were divided into two groups based on having pathological myopia or not. Predictability, efficacy, safety, and adverse events were compared at 6 months after pIOL implantation.
Our study included 86 non-pathological myopes (171 eyes, group1) and 14 pathological myopes (21eyes, group2) to analysis. The average ages were 25.5 and 33.0, respectively, and the spherical equivalent (SE) were -9.31D and -17.50D pre-operation. Six months after pIOL implantation, the SE were 0.00 and -0.50, respectively, and the refraction changes were statistically significant (P ≤ 0.05). Six months after surgery, 76.92% and 80.41% were within ± 0.50 D of the target and 92.31% and 95.88% were within ± 1.00 D. All eyes had unchanged BCVA or gained 1 or more lines in both groups and mean BCVA both improved a line 6m after operation. The efficacy index in the two groups were 0.95 and 0.88 and the safety index were 1.20, 1.33, respectively which was significantly different (P ≤ 0.05). Over the 6-month follow-up, no cataract, pigment dispersion glaucoma, pupillary block, or other vision-threatening complications happened, either.
The pIOL performed well for the correction of both non-pathological and pathological myopia throughout the 6-month observation period. The clinical outcomes of pIOL implantation for non-pathological myopia are essentially equivalent to those for pathological myopia.
比较后房型有晶状体眼人工晶状体（pIOL）植入术治疗非病理性近视和病理性近视的临床疗效。
本回顾性病例系列研究于 2017 年 7 月至 2021 年 10 月在北京同仁医院进行，纳入 100 例（192 只眼）连续接受 pIOL 植入术的患者。根据是否患有病理性近视，将患者分为两组。比较两组患者术后 6 个月时的预测性、有效性、安全性和不良事件。
本研究纳入 86 例非病理性近视患者（171 只眼，组 1）和 14 例病理性近视患者（21 只眼，组 2）。两组患者的平均年龄分别为 25.5 岁和 33.0 岁，术前等效球镜（SE）分别为-9.31D 和-17.50D。pIOL 植入术后 6 个月，SE 分别为 0.00 和-0.50，屈光度变化有统计学意义（P ≤ 0.05）。术后 6 个月，76.92%和 80.41%的患者屈光度在±0.50D 以内，92.31%和 95.88%的患者屈光度在±1.00D 以内。两组患者均未见 BCVA 改变或提高 1 行以上，术后 6 个月时平均 BCVA 均提高 1 行。两组的有效性指数分别为 0.95 和 0.88，安全性指数分别为 1.20、1.33，差异均有统计学意义（P ≤ 0.05）。术后 6 个月内，两组均未发生白内障、色素性青光眼、瞳孔阻滞或其他威胁视力的并发症。
pIOL 治疗非病理性近视和病理性近视的效果良好，在 6 个月的观察期内效果稳定。pIOL 植入术治疗非病理性近视的临床效果与病理性近视基本相当。
